Table 1. Demographic and hematological characteristics of the study’ cohorts.

Age, median (range)

81 (79–87)

73 (47–78)

70 (28–80)

< 0.001*

Age, median (range)

73 (47–78)

70 (28–80)

0.056

Sex, F/M

18/18

19/23

24/26

0.914

BMI (kg/sm²), median (range)

Not available

24.3 (19.4–36.1)

24.8 (18.6–39.7)

0.872

Time (months) from diagnosis to vaccination, median (range)

72 (3–213)

74 (2–306)

0.266

Time (months) from beginning of ongoing therapy to vaccination, median (range)

9 (1–111)

39 (1–209)

< 0.001

Number of lymphocytes/µL, median (range)

1150 (430–2300)

1810 (240–4300)

<  0.001

Number of neutrophils/µL, median (range)

1800 (700–23100)

3580 (1400–34400)

< 0.001

Lines of therapy, median (range)

2 (1–5)

1 (1–4)

0.003

Ongoing treatments

PI-based n = 9

VTD n = 2

VMP n = 2

VCD n = 1

IRD n = 2

KRD n = 1

PVD n = 1

Hydroxycarbamide n = 20

Daratumumab-based

DRD n = 14

Tyrosine kinase inhibitors n = 20

Imatinib n = 7; nilotinib n = 7; dasatinib n = 4; bosutinib n = 2

Imids-based n = 19

Lenalidomide+dex n = 17

Pomalidomide+dex n = 1

ERD n = 1

Ruxolitinib n = 6

Interferon alpha n = 2

Anagrelide n = 2

Diagnosis

Chronic myeloid leukemia n = 20

Essential thrombocythemia n = 11

Myelofibrosis n = 8

Polycythemia vera n = 11